logo
Fungal infections are ‘taking over the world'. Can they be stopped?

Fungal infections are ‘taking over the world'. Can they be stopped?

Yahoo07-04-2025

Blood congealed 'like black sausage', sexually-transmitted athlete's foot, and bloodstream-born pathogens untreatable with existing drugs. These are the kinds of fungal infections Professor Darius Armstrong-James, Infectious Diseases and Medical Mycology at Imperial College London, is used to treating.
'Probably about a third of the world is infected by some kind of fungus,' says Prof Armstrong-James, 'mostly skin, mucocutaneous, vaginal candidiasis, athlete's foot. Those kinds of fungi that aren't deadly but they are increasing in resistance'.
More lethal fungal varieties are spreading too: invasive fungal infections are killing an estimated 2.5 million people each year – twice the global fatalities of tuberculosis.
The world remains critically underprepared for fungal infections, the World Health Organization (WHO) warned this week, with a lack of diagnostic tests, effective treatments, and surveillance creating an urgent need for research.
But how serious is the problem?
The WHO's fungal priority pathogens list, compiled in response to this rising public health threat, is an itch-inducing read.
'Critical priority' fungi with mortality rates of up to 88 per cent take the top spots.
'Black fungus' or Mucormycosis, which turns tissue into black lesions, made headlines during the Covid-19 pandemic when 51,000 cases were reported in India.
'It invades very often through the nose, and then it can get into the eyes […] down the optic nerve into the brainstem and kills you,' Prof Armstrong-James told the Telegraph.
'We have to give [patients] all the strongest drugs we can find…cut out all of the infected tissue which often means major surgery to the face and half their brain'.
For some patients, the amount of blackened tissue that needs removing is so extreme it's impossible and they die within days.
Yet Mucorales, the fungal family which causes Mucormycosis, is not one considered 'critical' by WHO ranking.
There are four invasive fungal pathogens deemed 'critical' on the list, and their insidious spores can even be found in the UK.
One of them, 'Candida albicans', can be found 'in about half the population inside our guts,' says Dr Rebecca Drummond, Associate Professor in antifungal immunity, University of Birmingham.
Aspergillus, another critical priority pathogen, is in fact so widespread that most people inhale between 100 to 1000 spores every day from the air we breathe.
Even the mould on bread can contain Mucor, a fungus that causes Mucormycosis.
So if these threats are so prevalent, why don't we hear about them?
Scientists say it's because those most at risk to fungal pathogens are people with weak immune systems, like patients living with HIV or on chemotherapy.
'Most fungal infections attack people who've already got existing illnesses, so they've either got weakened immune systems or they've got problems with their lungs' Prof Armstrong-James says. 'Because they don't strike down the man or woman in the street, so to speak, they don't enter into the public folklore in the same way that viruses and bacteria do.'
As medical interventions have improved – think of advances in chemotherapy that have enabled a much greater number of cancers to be treated – there are now more people living with compromised immune systems who are vulnerable to deadly spores.
Grace*, 66, has long suffered from severe asthma. Just over 10 years ago, she was diagnosed with Chronic Pulmonary Aspergillosis (CPA) and Allergic Bronchopulmonary Aspergillosis, a lung-damaging, life-threatening, condition caused by the fungus Aspergillus fumigatus – another of the WHO's priority pathogens.
'I'd get my children to do back patting exercises to try and loosen [the mucus], I'd be on the floor over the cushions trying to be a bit upside down.' Scans finally revealed the extent of the infection.
'One of [the doctors] said: 'We know it's not cancer, because [with] the amount of patches you've got, you wouldn't be here,' she said, referring to the dark blotches of lung damage visible by x-ray.
Cocktails of antifungal drugs made her hair fall out and damaged her liver function.
Now, her lungs bleed daily, 'it's fresh blood, you can just suddenly feel it in your chest'.
Her breathing is inhibited by what she called 'basically a ball of fungus' in her lungs that has taken hold, causing inflammation and pulmonary cavities – small air-filled spaces within the lung tissue.
The fungal strain that is causing Grace's agony is found in soil across the UK, including in her native Wales, and she believes she caught the infection when she moved into her house while it was still being built.
'My doctors asked me at the time: 'Any idea how you've got this?' […] I bet it was moving into a building site, all the earth is being churned up, diggers going past, and dump trucks going past with soil on.'
A decade later, Grace is terrified of catching any further chest infections or bursting a blood vessel.
'My life has become much smaller,' she said.
She relies on daily intravenous antifungal drugs, a treatment so expensive that her doctors had to lobby the Welsh government to sign off on it.
She's adamant that an earlier diagnosis would have helped her.
'If your asthma's getting out of control, if antibiotics aren't really solving the problem, you need to be tested for fungal disease.'
Fungi have already been pivotal in some of the biggest public health crises of recent decades.
'In Covid, around 10 to 15 per cent of intensive care patients actually had secondary infection with Aspergillus,' says Prof Armstrong-James, 'for these patients, their risk of death was two to three times higher.'
Just this week, the UK Health and Security Agency (UKHSA) issued a warning of a 'rapidly emerging' fungal pathogen, Candida auris, undetected until 2009, which has now spread into hospitals globally.
'Candida auris is an antimicrobial-resistant pathogen that's slowly taking over the world,' says Prof Armstrong-James.
The rise of drug-resistant fungi like Candida auris are increasingly concerning for researchers and clinicians, with some scientists describing the phenomenon as a 'silent pandemic'.
Just as bacteria develop resistance to the antibiotics used to treat them if they are overused, so too do fungi adapt to resist drugs, dramatically limiting doctors' ability to treat infected patients.
But experts warn that drug resistance is also an environmental issue.
'Antifungal drugs that we would use in the clinic to treat infections are actually the same types of antifungal drugs that we would use in agriculture to protect plants…there's evidence now that before patients even had an antifungal drug, they're already infected with drug resistant strains, and it's because the fungus has picked up the drug resistance in the environment' Dr Drummond told The Telegraph.
Climate change could also be contributing to the problem.
Most fungal species cannot grow above 37 degrees celsius, and some researchers hypothesise that we might have even evolved to have this body temperature to keep fungi at bay.
But experts now fear that rising global temperatures are helping fungi adapt to warmer climates.
'About 99 per cent of [fungi] don't grow anywhere near body temperature… the ones that do grow near body temperature can cause dangerous infections. That's basically the primary rule as to whether a fungus can be a pathogen,' says Prof Armstrong-James.
'[But] because of global warming, more and more so-called non-pathogenic fungi are spending more and more time adapting to temperatures that could enable them to cause invasive infections in humans'.
Between 2009 and 2019, researchers discovered a fungus at a hospital in China which had never before infected people, but was making two patients sick. It was already resistant to two antifungal drugs.
The fungus, when kept at 37 degrees – the temperature of the human body – mutated 21 times faster than when it was kept at a cooler 25 degrees.
Not only did it thrive at body temperature, but when exposed to heat, its resistance to a third drug increased, leaving it virtually untreatable with existing medicines.
Climate change is also thought to have contributed to an explosion in cases of Valley fever, an infection caused by inhaling fungal spores which grow in soil in the southwestern US, northern Mexico, and parts of Central and South America. Between 1998 and 2015, cases went up 400 per cent, according to the CDC.
The reason for the increase? More dust storms.
So with deadly fungal pathogens that are able to resist our best drugs being spread by climate change, what is needed to counter the threat?
'We don't have a big backlog of new antifungal drugs coming up behind the ones we already have. So once we lose access to these antifungal drugs, if resistance becomes that bad, we're not going to have an awful lot to come up behind it,' says Dr Drummond.
Creating new treatments to kill fungi is also difficult because they are biologically so similar to humans.
'The closest relative to fungi, the fungal kingdom, is us,' says Dr Drummond, 'the biochemistry of the fungal cell is very similar to our cells, which means that if you're trying to find a drug that's going to kill the fungus, you have to be really sure it's not gonna be toxic to us as well.'
Dr Yukiko Nakatani, WHO Assistant Director-General for Antimicrobial Resistance, says: 'Not only is the pipeline of new antifungal drugs and diagnostics insufficient, there is a void in fungal testing in low- and middle-income countries, even in district hospitals. This diagnostic gap means the cause of people's suffering remains unknown, making it difficult to get them the right treatments.'
In the last decade, only four new antifungal drugs have been approved for use in the United States of America, the European Union or China.
As the clinical pipeline struggles to keep pace with growing drug resistance, the WHO warns that an urgent increase in research and development is critical.
Next week, The Last of Us, a television series depicting a post-apocalyptic world in which civilisation has been brought down by a parasitic fungus that turns people into zombie-like creatures, will be back on our screens.
But how close are we to a real fungal pandemic?
Dr Drummond thinks it's unlikely; fungi don't spread between people in the way shown on the show and the Cordyceps fungus it is based on usually prefers insects.
But, she warns, fungal infections 'will cause lots of problems over time if we don't deal with it now'.
*Names have been changed to protect identities
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

3 Healthcare Stocks Skating on Thin Ice
3 Healthcare Stocks Skating on Thin Ice

Yahoo

timean hour ago

  • Yahoo

3 Healthcare Stocks Skating on Thin Ice

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio

Arkansas ranks 45th for child well-being in national report, despite modest gains
Arkansas ranks 45th for child well-being in national report, despite modest gains

Yahoo

timean hour ago

  • Yahoo

Arkansas ranks 45th for child well-being in national report, despite modest gains

LITTLE ROCK, Ark. – Arkansas ranks 45th in the nation for overall child well-being, according to the 2025 KIDS COUNT Data Book released Monday by the Annie E. Casey Foundation. The annual report evaluates how children are doing across all 50 states in four areas: economic well-being, education, health, and family and community. 6-year-old Dennis Martin still missing after disappearing in Smokies in 1969 Though Arkansas has made some gains since the COVID-19 pandemic, the state continues to fall behind on most indicators compared to national averages. One area of progress is child poverty. The number of Arkansas children living in poverty has dropped by 7,000 since 2019. Still, 21% of the state's children remain in poverty, which is higher than the national rate of 16%. 'This report shows that while there has been some improvement, too many of our children are still being left behind,' said Keesa Smith-Brantley, executive director of Arkansas Advocates for Children and Families. 'We can't be satisfied with small gains when the overall trends remain troubling.' Racial disparities remain a serious issue. Officials said Black children in Arkansas face a poverty rate of 43%. Children of two or more races have a poverty rate of 21%, while 19% of Hispanic or Latino children live in poverty. Non-Hispanic White children have the lowest poverty rate at 15%. Ohio girl with brain injury from flu complications returns home In addition to being ranked 44th for child poverty, Arkansas is in the bottom 10 states on the following indicators: Teens ages 16-19 not attending school and not working 8th graders below proficient on math level Low-birthweight babies Child and teen deaths Teens ages 10-17 who are overweight or obese Children in single-parent families Children living in high-poverty areas Teen birth rate 'If you look at the data, teens are where we're falling further behind,' Smith-Brantley said. 'We're seeing more teens out of school and unemployed, and more who are overweight or obese. These are outcomes tied directly to the decisions our leaders are or aren't making.' For more information, visit Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Healing Shingles Naturally: How East Meets West in Fighting Viral Pain and Brain Risk
Healing Shingles Naturally: How East Meets West in Fighting Viral Pain and Brain Risk

Epoch Times

time3 hours ago

  • Epoch Times

Healing Shingles Naturally: How East Meets West in Fighting Viral Pain and Brain Risk

Shingles, also known as herpes zoster, is a viral infection that causes a painful, blistering rash and often affects older adults or those with weakened immune systems. But since the COVID-19 pandemic, shingles has been appearing in unexpected age groups—raising new concerns about immunity, stress, and long-term health risks. Without timely treatment, this condition can lead to serious complications, including persistent nerve pain and even cognitive decline. In an episode of the 'Health 1+1' program, Jonathan Liu, a Canadian professor of Traditional Chinese Medicine, discussed both Western and TCM approaches to treating the infection, along with immune-boosting medicinal recipes that may help reduce the risk of shingles. The Importance of Early Treatment The primary treatment for shingles involves antiviral medications such as famciclovir or valacyclovir, which are typically taken orally. In more severe cases, intravenous acyclovir may be used, particularly in hospitalized or immunocompromised patients. Liu emphasized that early intervention is crucial. Ideally, antiviral therapy should begin before blisters appear. The medication works by suppressing viral replication rather than repairing tissue damage; therefore, starting treatment more than three days after the onset of blisters may significantly reduce their effectiveness.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store